Most immunizations have not been well studied in patients with drug-induced immune suppression. This article reviews strategies for administering vaccines to patients with rheumatoid arthritis who are taking disease-modifying antirheumatic drugs.
A ccording to the CDC, in 2007, about 1.5 million adults in the United States had rheumatoid arthritis (RA). 1 In 2008, the American College of Rheumatology published recommendations for the use of disease-modifying antirheumatic drugs (DMARDs) and biologic agents in patients with RA; this report was updated in 2012. 2 These recommendations demonstrate the increasingly important roles these immunosuppressant agents have for reducing disease progression and improving quality of life for patients with RA. Many of these same agents are also regularly integrated into management plans for patients with other chronic autoimmune diseases, such as lupus erythematosus, infl ammatory bowel disease, and psoriatic arthritis.
The safety and effi cacy of immunizations in patients with RA and other autoimmune diseases can be a clinical controversy. Patients may have a reduced immunologic response, bringing into question the utility of administering vaccines. Also, researchers do not know if immunizations precipitate clinical worsening in patients with RA or put them at higher risk for vaccine-related adverse reactions. To complicate matters, patients with RA already are at increased risk for infection. 3, 4 In fact, patients with RA have an increased age-adjusted all-cause mortality, and frequent opportunistic and common infections contribute to that increased mortality. 5 The extent of immune suppression that occurs with DMARDs has not been established, but biologic agents carry black box warnings about increased infection risk. In contrast, corticosteroids, when used longer than 2 weeks and at doses greater than or equal to 20 mg/day of prednisone or the equivalent, are known to raise infection risk largely because of impaired T-cell production. 6, 7 Administering live vaccines to patients who have received long-term, high-dose corticosteroid therapy is not recommended because of the risk of infection coupled with the possibility of an inadequate immune response from the vaccine. Acute risk of a tetanus infection or exposing a neonate to pertussis could be compelling reasons to vaccinate a corticosteroid-exposed individual. If a patient is vaccinated while on high-dose corticosteroid therapy, providers should consider checking antibody titers and revaccinating if necessary. Another option is simply revaccinating after the patient achieves immune competency, although achieving competency can take 6 months to a year depending on the extent of therapy. Table 1 outlines administration recommendations for selected vaccines.
Most immunizations have not been well studied in immunocompromised patients, particularly those with drug-induced immune suppression. Despite limited evidence, recommendations are available for these populations; however, they require PAs to perform individualized risk and benefi t analyses for each immunization. The most effective strategy is to vaccinate patients with RA before they begin taking immunosuppressive agents. In a recent article, Thome offers three reasons to vaccinate fi rst:
• Patients with impaired immune function experience decreased responses to vaccines, thus vaccinating fi rst can improve the odds for a positive immunologic response.
Are immunizations safe and effective for patients being treated with immunosuppressive agents?
• The risk of invasive infection increases when patients become immunocompromised, thus vaccinating fi rst may help avoid serious infection.
• Live vaccines are often contraindicated for patients with both primary and secondary immune defi ciency, thus vaccinating fi rst may represent the only opportunity to safely immunize them. 8, 9 Additional research about the safety and effi cacy of immunization in patients receiving immunosuppressive therapy is needed. The relevance of this question will increase as the number of patients diagnosed with RA and the number of immunosuppressive drugs available for treatment continue to increase. JAAPA
